MD vs. AMED, AMN, CCRN, LH, DGX, DVA, CHE, CRVL, SEM, and EHC
Should you be buying Pediatrix Medical Group stock or one of its competitors? The main competitors of Pediatrix Medical Group include Amedisys (AMED), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), CorVel (CRVL), Select Medical (SEM), and Encompass Health (EHC).
Pediatrix Medical Group vs. Its Competitors
Amedisys (NASDAQ:AMED) and Pediatrix Medical Group (NYSE:MD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership.
Amedisys has higher revenue and earnings than Pediatrix Medical Group. Pediatrix Medical Group is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.
Amedisys currently has a consensus price target of $100.75, suggesting a potential upside of 3.69%. Pediatrix Medical Group has a consensus price target of $16.67, suggesting a potential upside of 18.88%. Given Pediatrix Medical Group's stronger consensus rating and higher possible upside, analysts plainly believe Pediatrix Medical Group is more favorable than Amedisys.
In the previous week, Amedisys and Amedisys both had 2 articles in the media. Amedisys' average media sentiment score of 1.29 beat Pediatrix Medical Group's score of 0.83 indicating that Amedisys is being referred to more favorably in the media.
Amedisys has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Pediatrix Medical Group has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
94.4% of Amedisys shares are held by institutional investors. Comparatively, 97.7% of Pediatrix Medical Group shares are held by institutional investors. 2.1% of Amedisys shares are held by company insiders. Comparatively, 0.9% of Pediatrix Medical Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Pediatrix Medical Group received 11 more outperform votes than Amedisys when rated by MarketBeat users. Likewise, 60.12% of users gave Pediatrix Medical Group an outperform vote while only 58.68% of users gave Amedisys an outperform vote.
Amedisys has a net margin of 3.57% compared to Pediatrix Medical Group's net margin of -4.92%. Pediatrix Medical Group's return on equity of 15.47% beat Amedisys' return on equity.
Summary
Amedisys beats Pediatrix Medical Group on 9 of the 17 factors compared between the two stocks.
Get Pediatrix Medical Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pediatrix Medical Group Competitors List
Related Companies and Tools
This page (NYSE:MD) was last updated on 6/13/2025 by MarketBeat.com Staff
